These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

752 related items for PubMed ID: 25313095

  • 1. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment.
    Papp K, Leonardi C, Menter A, Thompson EH, Milmont CE, Kricorian G, Nirula A, Klekotka P.
    J Am Acad Dermatol; 2014 Dec; 71(6):1183-1190.e3. PubMed ID: 25313095
    [Abstract] [Full Text] [Related]

  • 2. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
    Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, Aras G, Li J, Russell CB, Thompson EH, Baumgartner S.
    N Engl J Med; 2012 Mar 29; 366(13):1181-9. PubMed ID: 22455412
    [Abstract] [Full Text] [Related]

  • 3. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI, Hooft L.
    Br J Dermatol; 2012 Oct 29; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [Abstract] [Full Text] [Related]

  • 4. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
    Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, Papp K, Spelman L, Toth D, Kerdel F, Armstrong AW, Stingl G, Kimball AB, Bachelez H, Wu JJ, Crowley J, Langley RG, Blicharski T, Paul C, Lacour JP, Tyring S, Kircik L, Chimenti S, Callis Duffin K, Bagel J, Koo J, Aras G, Li J, Song W, Milmont CE, Shi Y, Erondu N, Klekotka P, Kotzin B, Nirula A.
    N Engl J Med; 2015 Oct 29; 373(14):1318-28. PubMed ID: 26422722
    [Abstract] [Full Text] [Related]

  • 5. Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis.
    Umezawa Y, Nakagawa H, Niiro H, Ootaki K, Japanese Brodalumab Study Group.
    J Eur Acad Dermatol Venereol; 2016 Nov 29; 30(11):1957-1960. PubMed ID: 27358210
    [Abstract] [Full Text] [Related]

  • 6. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.
    Nakagawa H, Niiro H, Ootaki K, Japanese brodalumab study group.
    J Dermatol Sci; 2016 Jan 29; 81(1):44-52. PubMed ID: 26547109
    [Abstract] [Full Text] [Related]

  • 7. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.
    Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, Toth D, Langley RG, Cather J, Gottlieb AB, Thaçi D, Krueger JG, Russell CB, Milmont CE, Li J, Klekotka PA, Kricorian G, Nirula A.
    Br J Dermatol; 2016 Aug 29; 175(2):273-86. PubMed ID: 26914406
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
    Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, Haemmerle S, Thurston HJ, Papavassilis C, Richards HB.
    Br J Dermatol; 2013 Feb 29; 168(2):412-21. PubMed ID: 23106107
    [Abstract] [Full Text] [Related]

  • 9. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
    Kimball AB, Gordon KB, Fakharzadeh S, Yeilding N, Szapary PO, Schenkel B, Guzzo C, Li S, Papp KA.
    Br J Dermatol; 2012 Apr 29; 166(4):861-72. PubMed ID: 22356258
    [Abstract] [Full Text] [Related]

  • 10. Brodalumab: the first anti-IL-17 receptor agent for psoriasis.
    Puig L.
    Drugs Today (Barc); 2017 May 29; 53(5):283-297. PubMed ID: 28650001
    [Abstract] [Full Text] [Related]

  • 11. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
    Gordon KB, Leonardi CL, Lebwohl M, Blauvelt A, Cameron GS, Braun D, Erickson J, Heffernan M.
    J Am Acad Dermatol; 2014 Dec 29; 71(6):1176-82. PubMed ID: 25242558
    [Abstract] [Full Text] [Related]

  • 12. Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study.
    Lebwohl MG, Blauvelt A, Menter A, Papp KA, Guenthner S, Pillai R, Israel RJ, Jacobson A.
    Am J Clin Dermatol; 2019 Dec 29; 20(6):863-871. PubMed ID: 31493163
    [Abstract] [Full Text] [Related]

  • 13. Long-term safety of brodalumab in Japanese patients with plaque psoriasis: An open-label extension study.
    Yamaguchi Y, Takatsu N, Ootaki K, Nakagawa H.
    J Dermatol; 2020 Jun 29; 47(6):569-577. PubMed ID: 32275086
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
    Barker J, Hoffmann M, Wozel G, Ortonne JP, Zheng H, van Hoogstraten H, Reich K.
    Br J Dermatol; 2011 Nov 29; 165(5):1109-17. PubMed ID: 21910713
    [Abstract] [Full Text] [Related]

  • 15. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
    Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, Morita A, Roseau K, Harfst E, Guettner A, Machacek M, Papavassilis C.
    Br J Dermatol; 2013 Feb 29; 168(2):402-11. PubMed ID: 23362969
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials.
    McMichael A, Desai SR, Qureshi A, Rastogi S, Alexis AF.
    Am J Clin Dermatol; 2019 Apr 29; 20(2):267-276. PubMed ID: 30471012
    [Abstract] [Full Text] [Related]

  • 17. Brodalumab: A Review in Moderate to Severe Plaque Psoriasis.
    Blair HA.
    Drugs; 2018 Mar 29; 78(4):495-504. PubMed ID: 29516365
    [Abstract] [Full Text] [Related]

  • 18. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
    Lebwohl MG, Kircik L, Callis Duffin K, Pariser D, Hooper M, Wenkert D, Thompson EH, Yang J, Kricorian G, Koo J.
    J Am Acad Dermatol; 2013 Sep 29; 69(3):385-92. PubMed ID: 23643256
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double-blind, placebo-controlled study.
    Seo SJ, Shin BS, Lee JH, Jeong H.
    J Dermatol; 2021 Jun 29; 48(6):807-817. PubMed ID: 33373480
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB.
    J Am Acad Dermatol; 2017 Mar 29; 76(3):418-431. PubMed ID: 28057361
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.